Cargando…

Effect of sorafenib on des-γ-carboxyprothrombin secretion by a human hepatocellular carcinoma cell line

Patients with hepatocellular carcinoma (HCC) who respond to sorafenib have been reported to exhibit an increase in the level of des-γ-carboxyprothrombin (DCP) in the blood, subsequent to the initiation of sorafenib treatment. In the present study, the levels of secretion of DCP and DCP with more γ-c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ogasawara, Sachiko, Nakayama, Masamichi, Akiba, Jun, Kusano, Hironori, Yano, Hirohisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530138/ https://www.ncbi.nlm.nih.gov/pubmed/28781657 http://dx.doi.org/10.3892/ol.2017.6451

Ejemplares similares

Des-γ-Carboxyprothrombin (DCP) and NX-DCP Expressions and Their Relationship with Clinicopathological Features in Hepatocellular Carcinoma
por: Sumi, Akiko, et al.
Publicado: (2015)

Antiproliferative effects of sorafenib and pegylated IFN-α2b on human liver cancer cells in vitro and in vivo
por: KUSANO, HIRONORI, et al.
Publicado: (2013)

Des-γ-Carboxyprothrombin Plasma Level in Diagnosis of Hepatocellular Carcinoma in a Chinese Population Undergoing Surgery
por: Feng, Xiaobin, et al.
Publicado: (2016)

Inclusive Quantification Assay of Serum Des‐γ‐Carboxyprothrombin Proteoforms for Hepatocellular Carcinoma Surveillance by Targeted Mass Spectrometry
por: Lee, Jihyeon, et al.
Publicado: (2021)

Prognostic value of des-γ-carboxyprothrombin in patients with AFP-negative HCC treated with TACE
por: Sun, Hanyao, et al.
Publicado: (2022)

Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: An Analysis of 4792 Patients
por: Pan, Yang-Xun, et al.
Publicado: (2021)

Utility of serum des-gamma-carboxyprothrombin in the diagnosis of hepatocellular carcinoma among Nigerians, a case–control study
por: Ette, Akpakip I., et al.
Publicado: (2015)

Combining des-gamma-carboxyprothrombin and alpha-fetoprotein for hepatocellular carcinoma diagnosing: an update meta-analysis and validation study
por: Chen, Huaping, et al.
Publicado: (2017)

CD44v3(+)/CD24(−) cells possess cancer stem cell-like properties in human oral squamous cell carcinoma
por: TODOROKI, KEITA, et al.
Publicado: (2015)

Aldehyde Dehydrogenase 1 Identifies Cells with Cancer Stem Cell-Like Properties in a Human Renal Cell Carcinoma Cell Line
por: Ueda, Kosuke, et al.
Publicado: (2013)

Pegylated Interferon-α2a Inhibits Proliferation of Human Liver Cancer Cells In Vitro and In Vivo
por: Kusano, Hironori, et al.
Publicado: (2013)

Des-gamma-carboxyprothrombin is a favorable biomarker for the early diagnosis of alfa-fetoprotein-negative hepatitis B virus-related hepatocellular carcinoma
por: Liu, Zhaobo, et al.
Publicado: (2020)

Diagnostic Value of hTERT mRNA and in Combination With AFP, AFP-L3%, Des-γ-carboxyprothrombin for Screening of Hepatocellular Carcinoma in Liver Cirrhosis Patients HBV or HCV-Related
por: Nguyen, Hoang Bac, et al.
Publicado: (2022)

Diagnostic value of alpha-fetoprotein, Lens culinaris agglutinin-reactive alpha-fetoprotein, and des-gamma-carboxyprothrombin in hepatitis B virus-related hepatocellular carcinoma
por: Song, Ting, et al.
Publicado: (2019)

Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol
por: Huang, Ting-Shuo, et al.
Publicado: (2013)

Expression and role of regulator of G‐protein signaling 5 in squamous cell carcinoma of the tongue
por: Abe, Yushi, et al.
Publicado: (2019)

Sorafenib as second‐line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2020)

Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments
por: Suzuki, Hiroyuki, et al.
Publicado: (2021)

The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE
por: Kimura, Yusuke, et al.
Publicado: (2020)

Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma
por: Ogasawara, Sadahisa, et al.
Publicado: (2016)

Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines
por: Zhang, Zhi, et al.
Publicado: (2020)

Impact of Gleason score of the tumor at the positive surgical margin as a prognostic factor
por: Kurose, Hirofumi, et al.
Publicado: (2022)

Synergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma
por: Yang, Xuran, et al.
Publicado: (2018)

Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines
por: D’Alessandro, Rosalba, et al.
Publicado: (2014)

Sorafenib as first-line treatment for patients with primary hepatocellular carcinoma: an outcome evaluation
por: Nguyen, Dung Thi, et al.
Publicado: (2023)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2016)

Synergistic effect of metformin on sorafenib in in vitro study using hepatocellular carcinoma cell lines
por: Chung, Yong-Gyu, et al.
Publicado: (2018)

Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib
por: da Fonseca, Leonardo Gomes, et al.
Publicado: (2018)

Muscle RAS oncogene homolog (MRAS) recurrent mutation in Borrmann type IV gastric cancer
por: Yasumoto, Makiko, et al.
Publicado: (2016)

ARHGEF15 overexpression worsens the prognosis in patients with pancreatic ductal adenocarcinoma through enhancing the motility and proliferative activity of the cancer cells
por: Fukushima, Hiroto, et al.
Publicado: (2016)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

Cancer‐associated fibroblast‐derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib
por: Eun, Jung Woo, et al.
Publicado: (2023)

KDM2A-dependent reduction of rRNA transcription on glucose starvation requires HP1 in cells, including triple-negative breast cancer cells
por: Okamoto, Kengo, et al.
Publicado: (2019)

Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma
por: Saif, Muhammad W., et al.
Publicado: (2011)

Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma
por: Almhanna, Khaldoun, et al.
Publicado: (2009)

Evolving role of Sorafenib in the management of hepatocellular carcinoma
por: Ziogas, Ioannis A, et al.
Publicado: (2017)

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
por: Ko, Yi-Ling, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dfoa76uktdk6hhcvf5et1rlltu